NEW CANAAN, Conn., March 27, 2025 /PRNewswire/ — Cheryl Pegus, MD, MPH, Executive Board Chair of FlyteHealth, is Co-Chair of the newly launched Capital Impact Council at the Duke-Margolis Center for Health Policy. This groundbreaking initiative “supports the development of strategies, tools, and frameworks to enable the private investment community to demonstrate and deliver measurable benefits for health outcomes, access, affordability, and community resilience.”

The Capital Impact Council (CIC) brings together venture capital and private equity investors along with Duke-Margolis Advisory Board Members to establish best practices for investments that lead to measurable improvements in the long-term health of communities. As a recognized leader in healthcare innovation and sustainable data-driven solutions, Dr. Pegus brings a wealth of expertise to the council.

“Private investment has enormous opportunity to drive innovation in health care, but to be truly transformative those investments must align with larger goals for affordability, sustainability, and long-term health outcomes,” said Dr. Pegus. “I’m honored to help lead this council to create tools that make public-private partnerships more impactful.”

Along with the announcement of the formation of the Council, the CIC issued “Health Value Return on Investment: A Framework to Support Private Investment that Improves Health Care and Health.” This resource provides a framework for assessing and measuring the long-term ROI of health care innovations.  

To learn more about the Capital Impact Council, visit https://healthpolicy.duke.edu/CIC.

About FlyteHealth
FlyteHealth is obesity care that empowers you. Delivering a comprehensive suite of clinical care, technology, and support, FlyteHealth reduces the complexity and cost of obesity and its comorbid conditions for employers and payers. Based on the founders’ decades of research and clinical care, FlyteHealth clinicians deliver the latest in personalized medication therapy and behavior coaching. The evidence-based treatment protocols enable individuals not only to lose weight and maintain weight loss long-term, but also to achieve significant improvements in outcomes related to diabetes, hypertension, heart disease, and many other weight-related health complications. Through the Flyte Intelligence obesity treatment platform, FlyteHealth empowers healthcare providers with subject matter expertise and care navigation services. Drawing from the largest data set of obesity and chronic disease research, Flyte Intelligence enables delivery of the highest standard of patient care at scale. For more information, please visit www.flytehealth.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/flytehealth-executive-board-chair-dr-cheryl-pegus-co-chair-of-newly-launched-duke-margolis-health-capital-impact-council-302412686.html

SOURCE FlyteHealth

SHANGHAI, March 27, 2025 /PRNewswire/ — Cango Inc. (NYSE: CANG), a rapidly expanding leader in Bitcoin mining, today announced key highlights from its filed annual report, marked by a successful pivot towards cryptocurrency mining and significant operational milestones, including securing its position as the third-largest publicly traded miner globally and a 400% year-over-year revenue increase. 

Fourth Quarter & Full Year 2024 Financial Performance

The Company achieved total revenues of RMB668.0 million (US$91.5 million) in Q4 2024, reflecting a 400% year-over-year increase. This growth was primarily driven by the launch of its Bitcoin mining business, which generated RMB653.0 million (US$89.5 million) in revenues. Net income for the quarter was RMB55.9 million (US$7.7 million), a notable turnaround from a net loss of RMB103.8 million in Q4 2023. Cango maintained strong liquidity with cash, cash equivalents, and short-term investments totaling RMB2.5 billion (US$345.3 million) as of December 31, 2024. 

For the full year, Cango reported total revenues of RMB804.5 million (US$110.2 million), with net income reaching RMB299.8 million (US$41.1 million), a significant turnaround from a net loss of RMB37.9 million in 2023. The results reflect the successful integration of Bitcoin mining operations alongside ongoing optimization of its legacy automotive services. 

Bitcoin Mining Operational Highlights

Cango deployed 32 exahashes per second (EH/s) of Bitcoin mining capacity in Q4 2024, securing its position as the third-largest publicly traded miner globally. During the quarter, the Company mined 933.8 Bitcoin, achieving an industry-leading efficiency of 17.81 BTC per EH/s. Operational costs were optimized, with an average fleet efficiency of 21.6 joules per terahash (J/TH) and a cash cost of US$67,769.9 per Bitcoin (excluding depreciation). As of December 31, 2024, Cango held a total of 933.8 Bitcoin, aligning with its long-term accumulation strategy. 

Cango’s mining operations span five countries, including the United States (38% of total hashrate), East Africa (37%), Oman, Paraguay, and Canada. Approximately 90% of its fleet comprises water-cooled Bitmain S19XP Hyd. machines, ensuring competitive energy efficiency and operational stability. 

Looking ahead, the Company plans to expand its hashrate to 50 EH/s by the end of July 2025 through the completion of its second-phase asset acquisition. Cango aims to further reduce energy costs by leveraging favorable regulatory developments in traditional energy markets and exploring partnerships for sustainable power solutions. Additionally, Cango is committed to enhancing its presence in the digital asset ecosystem while maintaining a disciplined approach to managing its Bitcoin holdings. 

Media Contact

Juliet Ye
Cango Inc.
Tel: +86 21 3183 5088 ext.5581
Email: ir@cangoonline.com 

View original content:https://www.prnewswire.co.uk/news-releases/cango-inc-presents-key-highlights-of-its-filed-annual-report-302413107.html

Wishpond enters into a collaboration agreement with Venops to market and sell Wishpond’s AI-powered SalesCloser platform, white-labeled as Provencis, to clients in healthcare and the medical industry.This collaboration underscores Wishpond’s commitment to expanding SalesCloser’s reach into new verticals and delivering tailored AI solutions that transform sales processes and empower businesses of all industries to achieve their goals.

VANCOUVER, BC, March 27, 2025 /CNW/ – Wishpond Technologies Ltd. (TSXV: WISH) (OTCQX: WPNDF) (the “Company” or “Wishpond”), a provider of AI-enabled marketing-focused online business solutions, is pleased to announce a collaboration agreement with Venops Inc. (“Venops”), a leader in healthcare regulatory compliance and consulting services, to market and sell Wishpond’s AI-powered SalesCloser platform, white-labeled as “Provencis”, to clients in the medical industry. With a network of over 1,000 medical clinics, Venops brings extensive professional and industry reach, combining its deep expertise in healthcare compliance with Wishpond’s innovative AI technology, this collaboration aims to revolutionize how businesses in the medical sector engage with prospects and drive sales.

Under the agreement, Venops will leverage its industry expertise and customer relationships to market Provencis, while Wishpond will provide the use of its SalesCloser platform, including AI virtual agents, platform hosting, and ongoing support. This collaboration reflects a shared commitment to delivering innovative solutions and represents a significant milestone for both companies in driving growth and innovation within the healthcare industry.

Ali Tajskandar, CEO of Wishpond, commented, “We are thrilled to collaborate with Venops to introduce our SalesCloser technology to the medical industry under the Provencis brand. This collaboration underscores our commitment to expanding SalesCloser’s reach into new verticals, delivering tailored AI solutions that aim to transform sales processes and empower businesses to achieve their goals.”

Mark Maloney, CEO of Venops, commented, “Collaborating with Wishpond allows us to provide our clients in the medical sector with a cutting-edge solution tailored to their unique needs. Provencis combines the power of AI with Venops’ regulatory expertise, creating a groundbreaking sales tool that transforms how businesses engage with prospects and drive sales.”

Provencis is a healthcare-focused generative AI solution designed to assist providers with patient care, administrative tasks, and sales operations. Venops aims to utilize Provencis to empower healthcare providers with AI tools that enhance patient outcomes, reduce complications and readmissions, ease administrative burdens, and enable more personalized care. Additionally, Provencis equips healthcare industry leaders with AI solutions that facilitate communication about their services and products to the professionals who need them. The vision of Provencis is to create a future where AI helps the healthcare ecosystem focus on what truly matters: the patient.

Provencis offers a range of applications tailored for different segments of the medical industry. In medical practices and in the medical industry, it serves as a virtual receptionist, answering calls without the need for a phone tree, providing details on hours of operation, services offered, insurance plans accepted, and scheduling appointments. It can refer callers to human representatives when necessary and collect information for staff follow-ups. In surgical centers and medical practices, it enhances post-surgery follow-ups by monitoring recovery progress, tracking pain levels and mobility, escalating concerns to providers, scheduling follow-ups, monitoring medication adherence, and ensuring continuity of care for chronic conditions like diabetes. In the medical device industry, it functions as an inbound sales agent, providing detailed information about new devices, implants, and procedures, gathering lead information, facilitating consultations through phone or web meetings, and ensuring seamless hand-offs to sales teams or customer service representatives.

Provencis is designed to be a scalable and cost-effective AI-powered platform that helps healthcare organizations manage high volumes of inquiries while reducing reliance on human representatives. Provencis is designed to deliver interactive virtual assistance, simplifies appointment and lead management, provides comprehensive patient education and support, integrates seamlessly with electronic medical records and CRM systems, and enhances operational efficiency. By leveraging AI to handle patient inquiries, administrative tasks, and sales processes, Provencis allows healthcare providers to focus on delivering high-quality patient care while improving overall efficiency.

This collaboration between Wishpond and Venops marks a significant step forward in the application of AI within the healthcare industry. By combining Wishpond’s expertise in AI-driven automation with Venops’ regulatory knowledge, Provencis has the potential to redefine how healthcare businesses interact with patients and manage their sales operations, ultimately driving better outcomes for providers and patients alike.

Ali Tajskandar
Chief Executive Officer
Wishpond Technologies Ltd.

About Wishpond Technologies Ltd.           

Wishpond is a Vancouver-based provider of AI-enabled marketing and sales solutions that help businesses grow more efficiently. The Company’s vision is to create a fully autonomous AI-enabled platform that streamlines the entire customer acquisition journey, from lead generation and engagement to deal closure, enabling businesses to scale cost-effectively while driving higher conversions. Wishpond offers an all-in-one marketing suite that integrates AI-driven tools such as an AI Website Builder, AI Email Automation, and SalesCloser AI, a conversational AI-based virtual sales agent that leverages generative AI to conduct personalized sales calls and product demos, increasing efficiency, reducing costs, and enhancing customer satisfaction. With a focus on innovation, Wishpond has filed multiple patent applications in conversational AI, reinforcing its leadership in AI-enabled marketing automation. The Company serves small-to-medium-sized businesses across various industries, providing a powerful yet cost-effective alternative to fragmented marketing solutions. Wishpond employs a Software-as-a-Service (SaaS) business model, generating most of its revenue from subscription-based recurring revenue, which ensures strong revenue predictability and cash flow visibility while continuously expanding its AI capabilities. Wishpond is listed on the TSX Venture Exchange under the ticker “WISH”, and on the OTCQX Best Market under the ticker “WPNDF”. For further information, visit: www.wishpond.com.

Forward-Looking Statements

Statements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about, among other things, the impacts of the collaboration agreement, references to the expected results of the Company’s collaboration with Venops, the expected performance of Provencis, references to expected results from future operations, future growth of the Company’s products and platforms, the future development and increased use of products incorporating artificial intelligence, including SalesCloser AI, references to the growth of the Company’s product portfolio and future profitability, including whether additional products or features may be developed in the future, and the functionality and timing of such products, financial results or operational activities that may be undertaken by the Company, expectations, beliefs and plans relating tofuture operations, the impact of broader economic factors including inflation and other general economic risks on the Company, and future events and performance. Sentences and phrases containing or modified by words such as “expect”, “anticipate”, “plan”, “continue”, “estimate”, “intend”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targets”, “projects”, “is designed to”, “strategy”, “should”, “believe”, “contemplate” and similar expressions, and the negative of such expressions, are not historical facts and are intended to identify forward-looking statements. Readers are cautioned to not place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and are based on, among other things, the expectations and analysis of current market trends and opportunities of management of the Company, such forward-looking statements has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including, but not limited to, the implementation, utilization and marketing of Provencis by Venops, economic uncertainty and instability as a result of the ongoing inflation and supply chain issues, higher interest rate climate, tightening of credit availability and recessionary risks, pandemic related risks, wars, instability in global commodity and securities markets, shifts in consumer and institutional spending and marketing strategies, risks related to data breaches and privacy, the changing global market and competition for the products and services supplied by the Company, and the additional risk factors discussed in the continuous disclosure materials of the Company which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wishpond-collaborates-with-venops-to-transform-professional-medical-engagements-with-ai-powered-salescloser-platform-302412927.html

SOURCE Wishpond Technologies Ltd.